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Abstract
Background: 17β-hydroxysteroid dehydrogenase type 3 (17βHSD3) deficiency is a rare cause of disorder of sex
development (DSD) due to impaired conversion of androstenedione to testosterone. Traditionally, the diagnosis
was determined by βHCG-stimulated ratios of testosterone:androstenedione < 0.8.
Case presentation: An otherwise phenotypically female infant presented with bilateral inguinal masses and a 46,XY
karyotype. βHCG stimulation (1500 IU IM for 2 days) suggested 17βHSD3 deficiency although androstenedione was
only minimally stimulated (4.5 nmol/L to 5.4 nmol/L). Expedient genetic testing for the HSD17B3 gene provided the
unequivocal diagnosis.
Conclusion: We advocate for urgent genetic testing in rare causes of DSD as indeterminate hormone results can
delay diagnosis and prolong intervention.
Keywords: 17β-hydroxysteroid dehydrogenase type 3 deficiency, Disorders of sex development, 46,XY
undervirilization
Background
Disorders of sex development (DSD) occur when there
is discordance among chromosomal, hormonal, and
phenotypic sex. They require prompt and timely diagno-
sis because certain etiologies can result in acute medical
decompensation. Even in the absence of a medical emer-
gency, ambiguous genitalia can present a social emergency
to the parents when ascribing a sex to their newborn child.
This can be further magnified if parents have already
become accustomed to the child being a certain sex. The
evaluation for the etiology of a DSD involves measurements
of hormones with genetic testing historically reserved for
confirmatory purposes. Hormonal assessments can direct
genetic testing, but results may not be straightforward and
can be influenced by a multitude of physiologic and
practical factors. We present a case of a rare cause of 46,
XY DSD where timely genetic testing resulted in a rapid
diagnosis. The unequivocal result of genetic testing facili-
tated a more confident execution of a management and
therapeutic plan.
Case presentation
A healthy 1-month-old female was referred to Pediatric
Endocrinology for bilateral inguinal masses. She was the
product of a non-consanguineous conception between
parents of English and English/German descent.
Physical examination revealed a healthy child with female
external genitalia. She had prominence of the labial folds
with palpable masses in the inguinal canals. There was a
urogenital opening without clitoromegaly. Pelvic ultrasound
demonstrated inguinal gonads and absence of uterus and
ovaries.
Due to the presence of inguinal gonads but absence of
Müllerian structures, investigations were pursued for causes
of undervirilization. Cytogenetic analysis confirmed a nor-
mal 46,XY complement. Baseline Luteinizing Hormone,
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Follicle Stimulating Hormone, and cortisol concentrations
measured at 6 weeks of age were 1.5 U/L, 1.6 U/L, and
621 nmol/L, respectively. Anti-Mullerian Hormone levels
were appropriate for an infant male, implying the presence
of functioning Sertoli cells. At 6 weeks of age, baseline
androstenedione level was 4.5 nmol/L and testosterone
1.1 nmol/L. These levels in themselves were elevated, and
the baseline testosterone:androstenedione (T:A) ratio of 0.2
hinted at the etiology of 17β-hydroxysteroid dehydrogenase
type 3 (17βHSD3) deficiency. However, even during the
mini-puberty of infancy, hormonal values of various causes
of 46,XY undervirilization can significantly overlap. The pa-
tient subsequently underwent a short βHCG stimulation
test 1500 IU daily for 2 days (Table 1). The diagnosis of
17β-hydroxysteroid dehydrogenase type 3 (17βHSD3) defi-
ciency was further suspected based on the low stimu-
lated T:A (testosterone 2.1 nmol/L, androstenedione
5.4 nmol/L, T:A 0.4). These results directed genetic testing
for 17βHSD3 deficiency. At the same time, the minimally
increased value of the stimulated androstenedione level
compared to the baseline (5.4 and 4.5 nmol/L, respectively)
called into question the adequacy of the stimulation testing.
Other causes of 46,XY undervirilization, such as 5-alpha re-
ductase deficiency, remained possible. Additionally, ap-
proval for genetic testing was not a given. Taking into
consideration the parents’ desire to cement a diagnosis, a
prolonged βHCG stimulation test (1500 IU twice weekly
for 2 weeks) was undertaken when the baby was 18 weeks
old (Table 1).
The evaluation and management of an infant born with a
DSD should be conducted in interdisciplinary teams with
experience in caring for these very rare conditions, includ-
ing endocrinology, genetics, urology, social work, and clin-
ical chemistry. At the same time, the particulars of the local
socio-political and geographic environment dictate the dis-
tribution of medical resources and, in our case, the avail-
ability of genetic testing. While the prolonged βHCG
stimulation test was transpiring, our multidisciplinary clin-
ical team pursued genetic testing for 17βHSD3 deficiency
as the most likely diagnosis on the basis of the clinical
evaluation and initial low T:A. This effort involved actively
petitioning for government funding to cover genetic testing
as per routine in our medical jurisdiction when genetic test-
ing is performed in a lab outside the province. We could
not be assured funding for genetic testing and pursued
prolonged βHCG testing during the limited time frame of
neonatal puberty. The prolonged βHCG stimulation testing
proved overwhelming for the family due to the multiple in-
jections, cost of βHCG, and the practicalities of their having
to travel back and forth from their remotely located home
to the laboratory. In addition, the parents were committed
to raising the baby as a girl and experienced considerable
anxiety over the presence of testes and the delays in
diagnosis.
DNA sequencing analysis for the HSDB173 gene was
conducted in a commercially available, FDA accredited
laboratory (Prevention Genetics, Marshfield, WI, USA)
by Sanger sequencing of the full coding regions of exons
1-11, as well as ~20 basepairs of flanking non-coding
DNA on either side of each exon. This revealed a homo-
zygous mutation, previously reported as pathogenic with
complete loss of enzymatic activity (c.389 A > G) [1].
Genetic analysis of the parents revealed that both were
heterozygous for the same mutation in the HSD17B3
gene. Array CGH analysis was completed using the
CytoSure TM ISCA 8x60K V2.0 Oligonucleotide array
(Oxford Gene Technology) and showed normal dosage
across the genome.
The genetic analysis was reported before the pro-
longed βHCG protocol was completed. Once funding
was approved, the prolonged testing was discontinued.
The cost of genetic testing was comparable to prolonged
βHCG stimulation testing. With the genetic diagnosis,
our team was able to provide focused, anticipatory guid-
ance and allay many of the parents’ anxieties.
Discussion
46,XY disorders of sex development (DSD) are uncom-
mon and may stem from disorders of androgen synthesis
in the adrenal glands or testes or disturbances in andro-
gen action [2]. Making a timely diagnosis is important to
prevent medical crises due to associated hormonal
Table 1 Hormone Levels and Ratios with βHCG Stimulation (SI units)
Short βHCG protocola Prolonged βHCG Protocol b Reference Ranges
Baseline Stimulated Baseline Stimulated
Androstenedione (A) 4.5 5.4 1.7 20.5 < 3.0 nmol/L
Testosterone (T) 1.1 2.1 < 0.2 10.9 < 14 nmol/L
Dihydrotestosterone (DHT) 227.7 559 N/A N/A 414–2933 pmol/L
T:A 0.2 0.4 0.5 > 0.8
T:DHT 4.8 3.7 N/A N/A > 10
Androstenedione (A) (RIA, DIAsource); Testosterone (T) (electrochemiluminescence, Roche); Dihydrotestosterone (DHT) (LC/MS/MS, Esoterix)
a1500 Units βHCG daily for two consecutive days at age 6 weeks. Stimulated levels were measured 24 h following the second injection
b1500 Units βHCG every other day (2 times per week) for 2 weeks at age 18 weeks. Stimulated levels were measured 24 h following the 3rd injection.
The Prolonged βHCG Protocol was discontinued when the genetic result became available. The protocols were adapted from [12]
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deficiencies. Identifying the etiology is also helpful in
assigning a sex of rearing, predicting response to hormo-
nal therapy in infancy, counselling about expected chal-
lenges at puberty, and guiding decisions regarding
gonadectomy. However, a lack of diagnosis can occur in
up to 50 % of cases with sexual ambiguity and a male
karyotype [3].
Deficiency of 17βHSD3 is a rare cause of XY undervirili-
zation affecting 1 in 147 000 live births [4]. This may be an
underestimate as patients with 17βHSD3 deficiency can be
incorrectly diagnosed with androgen insensitivity syndrome
(AIS) [5]. The 17βHSD3 enzyme is present mainly in tes-
ticular tissue and converts the relatively weak androgen,
androstenedione, to its potent metabolite, testosterone.
There are at least 12 isoforms of 17βHSD present in organs
including the liver, brain, and skin [6, 7]. Impairment of
testosterone synthesis during fetal development results in
undervirilization of male external genitalia. Although tes-
tosterone synthesis is insufficient, Anti-Müllerian Hormone
production remains intact, leading to absence of internal
Müllerian structures. The phenotypic spectrum ranges
from normal-appearing female external genitalia to micro-
phallus with hypospadias and variable degrees of genital
ambiguity in between [7].
Assessment of basal hormone levels is typically the first
step in diagnosis. Baseline androstenedione, testosterone,
and dihydrotestosterone (DHT) levels and their ratios may
help discriminate between 17βHSD3 deficiency and other
causes of 46,XY DSD [4, 8]. However, considerable overlap
in hormone levels has been shown [4, 5, 8, 9]. A T:A less
than 0.8 was originally thought to be diagnostic of
17βHSD3 deficiency [4, 5]. This ratio only applies if there is
an observed stimulation of androstenedione because low
T:A can be seen in other defects in testosterone synthesis,
including Leydig cell hypoplasia and testicular dysgenesis.
In our case, while the baseline and stimulated levels and
ratios suggested the possibility of 17βHSD3 deficiency, the
baseline and stimulated levels did not differ significantly
from one another; the T:A ratio of less than 0.8 could not
by itself be used to diagnose 17βHSD3 deficiency. Unfortu-
nately, there is no consensus as to the minimum threshold
of androstenedione that reflects adequate βHCG stimula-
tion. Variations in assays may, in part, underlie the overlap
observed among hormone results.
Beta-HCG stimulation testing does not definitively diag-
nose 17βHSD3 deficiency nor distinguish it from other
causes of 46,XY DSD. In patients with genetically-proven
HSD17B3 mutations, βHCG stimulation does not consist-
ently stimulate androstenedione levels, making it challen-
ging to interpret a T:A ratio [9, 10]. Other studies have
demonstrated that the T:A ratio can be > 0.8 before and
after βHCG stimulation in proven cases of 17βHSD3 defi-
ciency; solely relying on T:A < 0.8 as a diagnostic criterion
would have ruled out the diagnosis [4, 9, 10]. One report
describes three related patients with stimulated T:A ratios
of 0.5, 1.5 and 3.4, even though they shared the same
HSD17B3 mutation (homozygous S232L) [10]. In another
study, a stimulated T:A ratio of < 0.8 falsely suggested
17βHSD3 deficiency in 4–6 % of patients with a confirmed
diagnosis of complete or partial androgen insensitivity
based on androgen binding studies and mutational ana-
lysis, and over half of the cases of testicular dysgenesis had
a low T:A ratio [5, 11]. These studies provide evidence
that the stimulated T:A ratio is not reliably diagnostic of
17βHSD3 deficiency. With our case, we pursued genetic
testing for 17βHSD3 deficiency to reach an unequivocal
diagnosis, given that neither baseline nor stimulated T:A
ratios are absolutely reliable.
Failure of hormone testing to elucidate clearly the cause
of XY undervirilization may relate to the variability and lack
of consensus among βHCG stimulation protocols. The pro-
tocols differ in dose and duration, ranging from 500 to
1500 units per day and as long as 2 days to one month [4,
8, 12–15]. Evidently there is no clear consensus on duration
or dose of βHCG, with most studies recommending an ini-
tial short course of βHCG followed by prolonged βHCG
stimulation if there is an inadequate rise in precursors such
as androstenedione or testosterone [12]. Our patient’s base-
line precursors did not increase much following the short
βHCG stimulation protocol. As a result, our patient under-
went a prolonged stimulation protocol, and the androstene-
dione demonstrated a more convincing rise from 1.7 to
20.5 nmol/L with the T:A ratio remaining < 0.8.
The parental perspective and experience during investi-
gations are essential considerations. In our case, the par-
ents were committed to raising their 1-month-old infant
as a girl, and they experienced significant emotional dis-
tress over the uncertainty of a diagnosis of 17βHSD3 defi-
ciency. We debated the timing of gonadectomy as a
previous literature review demonstrated that early orchi-
ectomy resulted in 100 % retention of the female gender
role while 54 % of patients changed to the male gender
role if orchiectomy was delayed [16]. Delaying gonadec-
tomy until puberty would provide the opportunity to ob-
serve whether the child was predisposed to a male gender
identity but may also theoretically contribute to gender
dysphoria [16]. However, these outcome data are limited
and based on a small sample of patients. A review of pub-
lished studies found that 39–64 % of female-assigned pa-
tients with 17βHSD3 deficiency underwent gender role
changes [16, 17]. It is also important to decide on gonad-
ectomy before puberty to prevent unintended virilization.
This is highlighted in case reports where phenotypic fe-
males were diagnosed with 17βHSD3 deficiency at pu-
berty after developing significant virilization. It is
hypothesized that androstenedione is converted to testos-
terone by extra-testicular 17βHSD isoforms at puberty,
and removal of the testes reduces the main source of
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androstenedione [18, 19]. Furthermore, there is a risk of
gonadoblastoma, quoted as high as 28 % in some studies,
and this risk should be factored into decisions on gonad-
ectomy [7, 20]. The decision about sex of rearing should
be made in light of the best possible prediction of future
sexual function, virilization, and satisfaction with gender
identity. These predictions are often only a best guess, fur-
ther blurred if the etiology is in question.
Historically, genetic testing for rare causes of DSDs has
been reserved for confirmatory purposes, guided by the
results of hormonal testing. In our case, we had enough
suspicion following the short-course βHCG stimulation
testing to rationalize the request for genetic testing for
17βHSD3 deficiency as the most likely diagnosis. In the
mean time, prolonged βHCG stimulation was initiated
with the hopes of clarifying the diagnosis and in case gen-
etic testing was denied. βHCG was not covered by insur-
ance for the baby’s specific indication, and the parents
were required to pay out-of-pocket for two vials. It re-
quired 3 extra medical appointments to receive the injec-
tions and 2 laboratory visits to draw the blood work. The
cost of genetic testing was $780 USD (Prevention Genet-
ics, Marshfield WI, USA). We advocate that this cost is
acceptable and that earlier genetic testing could mitigate
against the financial and human costs associated with sole
reliance on equivocal, hormone-based investigations.
Genetic and molecular knowledge, research, and
innovation are rapidly changing the way we investigate,
diagnose, and treat medical conditions. Recent advance-
ments in genetic testing have allowed for more cost-
effective methods using gene panels to test for genetically
heterogeneous Mendelian conditions [21]. Single-gene test-
ing is preferred if, following clinical and laboratory evalua-
tions, a specific diagnosis is likely, as demonstrated by our
case. However, in many centres, including ours, genetic
testing and confirmation are not readily accessible due to
lack of testing facilities and/or prohibitive costs. These
issues can also cause undue delay. Therefore, although the
utility of genetic testing is well-appreciated, clinical use of
these tests in an expedient manner is not yet optimally
implemented. The intended ears for our plea belong not
only to we who care for patients with DSD, but also to
policy-makers, researchers, governments, and funding
agencies, so that we may work together to improve access
to these technologies.
Conclusion
Sex assignment in an infant with a 46,XY disorder of sex
development can be a social emergency because it
requires urgent decision-making about the sex of rearing
and considerations of potential fertility, the role of
gonadectomy, and future gender identity. We contend
that such decisions should not be made without a con-
certed effort to confirm the diagnosis. Many publications
recommend βHCG stimulation to aid in the diagnosis,
but βHCG-stimulated hormone results can be unreliable
with overlap across diagnoses. The appropriate protocol
for βHCG stimulation remains uncertain. It seems rea-
sonable to try a short βHCG stimulation test to direct
confirmatory genetic testing. With recent advancements
in the field of clinical and molecular genetics, we advo-
cate for a more prominent role for, and more expedient
access to, urgent genetic testing to enable early and
accurate diagnosis of rare DSDs.
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